Krystal Biotech ( (KRYS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Krystal Biotech shares moved higher after the company reported strong early-stage clinical data for its inhaled gene therapy KB407 in cystic fibrosis. The Phase 1/2 and CORAL-1 molecular results showed that the treatment successfully delivered and expressed normal CFTR protein across treated airway cells, with broad lung transduction in both patients who are eligible for existing CFTR modulators and those who are not. Side effects were mostly mild and temporary, which supports the company’s plan to pursue repeat dosing and to seek FDA agreement on a registrational-intent CORAL-3 trial. On top of this, analysts raised their valuations following solid quarterly results, ongoing international expansion, and growing confidence that Krystal’s inhaled gene-delivery platform could be applied to additional pipeline programs, even as investors wait for future lung function data to confirm a clear clinical benefit.
More about Krystal Biotech
YTD Price Performance: 0.96%
Average Trading Volume: 297,895
Technical Sentiment Signal: Buy
Current Market Cap: $7.14B
For further insights into KRYS stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.